It is time-consuming to process and compare the clinical and marker information registered during monitoring of breast cancer patients. To facilitate the assessment, we developed a computer program for interpreting consecutive measurements. The intraindividual biological variation, the analytical precision profile, the cutoff limit, and the detection limit for each marker are entered and stored in the program. The assessment procedure for marker signals considers the analytical and biological variation of the applied markers. The software package contains a database that can store the interpretation of the measurements as evaluation codes together with patient demographics, information about treatment type, dates for treatment periods, control periods, and evaluation codes for clinical activity of disease. The consecutive concentrations for a patient are imported temporarily into the program from outside sources and presented graphically. Marker concentrations to be compared are selected with the computer mouse and the significance of the difference is calculated by the program. The program has an option for calculating the lead time of marker signals vs clinical information. The program facilitates the monitoring of individual breast cancer patients with tumor marker measurements. It may also be implemented in trials investigating the utility of potential new markers in breast cancer as well as in other malignancies.
Many compounds have been studied in the search for tumor markers that rapidly and reliably reflect treatment response of the individual breast cancer patient or give an early prediction of recurrence or new metastases (1) (2) (3) .
Longitudinal monitoring studies necessitate a standardized set of criteria for marker assessment (4, 5 ) . However, calculation of the significance of a change in concentrations is very time-consuming if performed manually (6, 7 ) . To facilitate this process, we have developed a computer program based on our model systems for tumor marker monitoring where the significance of a change is related to the normal inherent intraindividual biological variation (CV i ) and the total analytical variation (CV a ) of the applied markers and assay methods, respectively (5) (6) (7) . The program performs all calculations needed to interpret consecutive measurements and matches and compares marker and clinical information.
Materials, Methods, and Results patients
We previously have compared the ability of cancer antigen 15.3 (CA 15.3), 4 carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA), and routine clinical procedures to signal changed disease activity among 204 metastatic breast cancer patients monitored during firstline chemotherapy and subsequent follow-up (7 ) . The majority of the calculations were performed without computer assistance. Here we provide data from 59 of the patients randomized to epirubicin treatment. All data were calculated, processed, and presented by use of the generated computer program.
tumor markers
The CA 15.3, CEA, and TPA concentrations were determined with commercial radioimmunoassays: CA 15.3 (International CIS), CEA (Kabi Pharmacia), and TPA (Byk-Sangtec). Blood specimens for marker analysis were sampled every 3-4 weeks according to scheduled time points. Each specimen was analyzed for CA 15.3, CEA, and TPA. The specimens were analyzed consecutively, and each specimen from an individual patient was analyzed in a separate assay run.
overview of the computer program
The computer program was written in Microsoft Visual Basic 3.0 under Windows 95/Windows 98. The organization, options, functions, and workflow of the program are summarized in Table 1 .
support section
Test catalog. The unit of measurement, the measuring range, the detection limit, and the cutoff limit provided in the package insert are entered into the "test catalog" together with the values for within-subject biological variation (not including analytical variation): 6.2% for CA 15.3, 9.3% for CEA, and 28.3% for TPA (5 ) . The analytical imprecision represented as a precision profile is determined by each department. The measuring range is divided into 20 intervals with the finest divisions where the precision profile is steepest. For each interval, the values for concentration and the corresponding analytical imprecision are entered into the program in a tabular format. A graphical presentation of the precision profile data with the detection and cutoff limit is optional. The imprecision corresponding to a selected concentration interval is shown by pointing at the precision profile with the mouse. The test catalog may hold information for up to 100 different marker assays and may be updated as new markers are implemented or measuring methods are improved or changed.
Evaluation codes catalog. The codes for clinical as well as marker assessment have to be entered into the "evaluation codes catalog" section. The clinical assessment of disease status according to WHO (8 ) comprises the following codes: (a) disappearance of all known disease [complete response (CR)]; (b) a decrease of Ն50% in total tumor size [partial response (PR)]; (c) an increase Ն25% in Table 1 . Workflow of the tumor marker evaluation program. a a The lower part of each screen provides information on how to proceed through each option. b The design of the program enables processing of data individually for different patient groups and trials. c The present version of the program is designed to process marker measurements and the corresponding dates imported as ASCII files. Import from other sources, i.e., Microsoft Excel, SPSS, and Statgraphics, is under development. d The underlined text indicates the options of the main menu in the program; Ⅲ denotes the suboptions. There is no consensus regarding interpretation of consecutive marker concentrations. Several criteria have been proposed (6, 7, 9 -34 ) . The data suggest that the criteria generated by Sölétormos and co-workers (6, 7, 34 ) , which considered the cutoff value, the duration of the change, and adjusted the significance of a difference to the background variation of the investigated marker, performed better than criteria where these parameters were not integrated into the assessment procedure (9 -34 ) . The high reliability of the criteria proposed by Sölétormos and co-workers (6, 7, ) has been substantiated in computersimulated models in which the different criteria from several authors were compared (34 ) . The criteria elaborated by Sölétormos and co-workers (6, 7, 34 ) as well as Table 2 . Printout of a patient record registered in the notebook database section. a a The panel shows demographic data for the patient MUUMARBI included in the trial MA 8702 with the registration number 39. The patient was treated with epirubicin.
The clinical examination program disclosed an initial phase of tumor regression followed by a phase of unchanged disease status before tumor growth. Basically, CA 15.3, CEA, and TPA provided the same information, but the changes in disease status were signaled earlier. The evaluation table provides both the evaluation codes and the corresponding dates of change registered for clinical disease activity and for the respective markers CA 15.3, CEA, and TPA. PRK denotes a status of unchanged partial response, and a date of change is not registered (7, 8 ) , the associated marker evaluation codes have been described in detail previously and summarized below: (a) significant decrement from above to below cutoff (complete marker response; CR); (b) significant decrement from above cutoff to a lower value above cutoff (PR); (c) significant increment from below to above cutoff or from above cutoff to a higher value (PD); (d) marker concentrations fluctuated and fulfilled neither response nor progression criteria [no change above cutoff (code NCH) or no change below cutoff (code NCL)]. Additionally, it may be necessary to have codes for steady-state conditions if the tumor marker information changes without a change in tumor status or vice versa [unchanged status of complete response (code CRK) or unchanged status of partial response (code PRK)].
patient database section Notebook. The "notebook" contains patient name, patient identification number (Pat.ID), patient registration number in a trial (Regist.no.), and the location of the patient. Table 2 shows a printout of a patient record. For each patient, the notebook can hold information of four treatment and control periods. The information to be entered is as follows: starting date of treatment, end of treatment (treatment I to treatment IV), end of control period (control period I to control period IV), and a remark (I-IV) of the type of treatment. Each of these eight periods has a table for storing four evaluation codes and the corresponding dates of change for each of the markers as well as for the clinical status of disease. The tables are accessed by clicking the treatment number (I-IV) listed on the first screen of the notebook. It is possible to select a printout of one or all eight evaluation tables. The program also provides an option for combining information from more markers in one evaluation code, which can be entered manually into the evaluation tables.
main section
Statistical methods. A major function of the program is to calculate the magnitude, the duration, and the significance of a change in concentration. A change in two concentrations is significant if the difference, expressed as a percentage of their mean value, exceeds ͌ 2 ⅐ Z ͌ (CV a 2 ϩ CV i 2 ) (35 ) . The ͌ 2 is a constant (for two measurements). The Z-statistic depends on the probability selected for significance and on whether the expected change is uni-or bidirectional. At P ϭ 0.05, Z ϭ 1.65 if the expected change is unidirectional (only one option, either an increment or a decrement) and Z ϭ 1.96 if bi-directional (two options because it is unknown whether the concentration will rise or fall). The CV a is the analytical imprecision of the prechange concentration, and the CV i is a populationbased intraindividual biological variation.
Graphical evaluation. The tumor marker concentrations and the corresponding dates of measurement are imported patient by patient into the program from outside sources. The data are stored in a temporary file, which is cleared when values for the next patient are imported or when the MA8702 denotes the trial code. Registr.no. 39 denotes the patient registration number in the trial. MUUMARBI denotes the name code. The lower part of the screen provides information on how to proceed to the next step in the graphical evaluation procedure (Fig. 2) . Activation of the PrintScreen option provides a print of the marker kinetics as presented above. Activation of the Exit option returns the program to the main menu ( Table 1 ). Fig. 2 . Printout illustrating the graphical evaluation option of CA 15.3 in an individual patient. E, concentrations obtained during the monitoring period. F, concentrations considered for the evaluation procedure. Tr I end denotes the end of first-line treatment for metastatic breast cancer (epirubicin) (7 ) . Start date denotes the sampling date of the concentration selected as the baseline against which other concentrations are tested (ddmmyyyy). Eval. date denotes the sampling date of the concentration tested for significance compared with the baseline concentration. The significance calculation was based on a two-side test because, theoretically, the concentrations following the selected baseline concentrations could either continue to decrease or increase. CV(a) denotes the analytical imprecision of the selected baseline concentration; CV(i) denotes the average intraindividual biological background variation determined in a healthy female population (5 ) . PD denotes CA153 progression February 28, 1989 . MUUMARBI denotes the name code for the presented patient. Pat.ID denotes the patient identification based on the date of birth, November 11, 1946 . Registr.no. denotes the registration number in the MA 8702 trial. R117 denotes the Department of Oncology R117, Herlev Hospital, University of Copenhagen, Denmark. Ͻ and Ͼ denote options for scrolling through those parts of the marker concentrations that are outside the screen. Activation of the PrintGraph option provides a printout of all concentrations, including those outside the screen.
program is closed. Up to four different markers for each patient may be selected simultaneously for the evaluation procedure. The sequential concentrations of the four markers and their respective cutoff limits are provided on the same screen to facilitate an overview ( Fig. 1 ; optional printout). Each graph can cover a time span of up to 3000 days, so it is possible to display patient data for more than 8 years.
By pointing and clicking with the mouse, the operator can enlarge a selected graph ( Fig. 2; optional printout) . If the patient's demographic data have been registered in the notebook, the program connects these data with the marker data, and markings on the graph indicating treatment starting point, endpoint, and end of control periods are obtained. The enlarged graph is presented with 500 days at a time and uses a scroll button to scroll through the entire course of measurements. The evaluation of data is performed on the enlarged graph. The first measure-ment of the pair to be compared is selected by the mouse. The point is color-marked; in addition, the concentration and the date of measurement are shown on the screen. The second measurement is then selected by the mouse, with the data also being shown on the screen together with the number of days between the two measurements. After the operator selects one-sided or two-sided testing, the program performs all further steps necessary for the significance test. Messages indicating "difference is significant" or "difference not significant" are shown on the screen. The tested significance levels are P Ͻ0.05, P Ͻ0.01, and P Ͻ0.001.
It is possible to select the evaluation code that describes the tumor marker interpretation from the list of codes presented as a drop-down list and to store the information (evaluation code and date of change in concentration) if the patient's demographic data have been entered beforehand in the notebook. Table 3 . Printout of a matching scheme for clinical and CA 15.3 evaluation codes. a a The data were cumulated from the 59 patients in the trial MA 8702 who received epirubicin in treatment period I for metastatic breast cancer. b The clinical disease status and the CA 15.3 information were not oppositely directed because the CA 15.3 concentrations had leveled off in a steady state below cutoff before tumor progression. There were more combinations of evaluation codes than patients because several patients had tumor regression in the initial phase of treatment followed by tumor growth. Accordingly, the evaluation codes for clinical disease status as well as for marker signals also changed. CRK denotes a status of unchanged complete response; PRK denotes a status of unchanged partial response; NC denotes no change of tumor burden compared with initiation of treatment; NCH denotes no change of above cutoff concentrations compared with initiation of treatment; NCL denotes no change of below cutoff concentrations compared with initiation of treatment; PDM denotes death without clinical signs of progression; ED denotes early death within 4 weeks after initiation of treatment (7, 8 ) .
Nongraphical evaluation. An option for testing the difference between two concentrations without importing all measurements for a patient is also available. The marker considered is selected from a drop-down list of available tumor markers (the "test list"), the first and second measurements are entered, one-sided or two-sided testing is selected, the "evaluate" option is clicked, and the result of the significance test is shown on the screen. If the patient's demographics are in the notebook, it is possible to store both the evaluation codes and the corresponding dates of change. A printout is optional. A manual evaluation can also be performed for patients not entered in the notebook, but then it is not possible to store either the evaluation codes or the dates of change in marker concentrations.
Match evaluation codes, list patients, and calculate lead time.
The program can be used to match the tumor marker evaluation codes with the clinical evaluation codes specified for each of the four evaluation numbers as well as to summarize the results of the matching process for all four evaluation numbers within a selected treatment or control period ( Table 3 ). The program also has an option for finding patients with a specified combination of marker and clinical evaluation codes and to calculate the marker lead time for concordant events (CR-CR, PR-PR, PD-PD; positive lead time, marker information precedes clinical information; negative lead time, clinical information precedes marker information; no lead time, the clinical and marker information is obtained simultaneously). After the treatment or control period and the evaluation number are selected, the marker evaluation code and clinical evaluation code to search for are selected by clicking the code from the drop-down code list. The program then finds the patients with the specified combination of codes, identifies the corresponding dates of change, calculates the lead times, and places the names, the patient identification number, and the patient registration number on a scroll list on the screen. A printout is optional (Table 4 ).
Discussion
Serological tumor markers have been the subject of several investigations suggesting a potential role in monitoring breast cancer. Most commercially available assays are recommended for monitoring purposes by the respective manufacturers. None, however, provides guidelines for interpreting sequential concentrations measured during therapy and follow-up.
Here we present a computer program that facilitates a standardized interpretation of sequential concentrations. The program is based on our previous studies of stochastic variation of tumor markers and on the use of normal a For positive lead time, marker information precedes clinical information; for negative lead time, clinical information precedes marker information; for no lead time, clinical and marker information is obtained simultaneously. The data were cumulated from all evaluations among the 59 patients with metastatic breast cancer treated with epirubicin during treatment period I in the MA 8702 trial (7, 8 ) .
biological variation and analytical imprecision to test the significance of a change in concentrations (5) (6) (7) . We have chosen to use a population-based mean intraindividual biological variation in combination with the analytical variation in the significance calculations because it seldom is possible to obtain information about the intraindividual variation of a marker in the single patient before disease, but any fraction (95th or 90th percentile) instead of the mean may be entered as CV i in the test catalog of the program if preferred. The selected level should, however, depend on whether a high sensitivity or a high specificity is considered important for the monitoring situation in question.
Previous studies from our group have documented that the simple use of cutoff limits for detecting unusual marker results for a particular individual has little value because significant changes in concentrations may occur within the reference range without any tumor being present and because changes from within to outside the reference range or vice versa are not necessarily significant (5 ) . However, if the cutoff limit is integrated together with the magnitude and duration of a change into criteria for assessment as recommended by Sölétormos and coworkers (6, 7, 34 ) , the marker information becomes more reliable than information obtained using criteria recommended by other authors (9 -33 ) .
Clinical trials on the utility of serological tumor markers may include an enormous amount of data with hundreds of patients and measurements of a large number of consecutive serum samples for each patient and marker. Standardized evaluation codes and standardized procedures for storing the codes are a prerequisite for computerized matching and comparison of marker and clinical data. We have designed the tables for storing and matching the evaluation codes with options for four treatment and control periods and four evaluations during each of these eight periods because both the activity of malignant disease and marker concentrations often show dynamic changes over time ( Table 2 ).
In conclusion, the presented computer program may be implemented to assess the performance of different tumor markers and to select the most reliable marker in terms of responsive and progressive breast cancer. When data that characterize the analytical and biological variability are available, the program may also be used to monitor other malignancies.
The computer program can be obtained by contacting the authors.
